Exploring the metabolic-immune score in advanced NSCLC treated with immunotherapy.

ABSTRACT: Identifying reliable prognostic markers in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) is critical for clinical decision-making. This study introduces the Metabolic and Immune Score (MIS), a novel scoring system combining metabolic and inflammatory markers. A retrospective analysis was conducted on 56 patients with advanced NSCLC treated with ICIs between January 2018 and January 2024. Baseline metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated using 18F-FDG PET-CT imaging. Systemic inflammatory status was assessed using the Lung Immune Prognostic Index (LIPI). Median values for MTV and TLG were used as cut-off points. Primary outcomes were progression-free survival (PFS) and overall survival (OS). P

SUBMITTER: Karaoglan BB 

PROVIDER: S-EPMC12371022 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature